Abstract:BackgroundAcute kidney injury (AKI) was a common clinical complication among critically ill patients in Intensive Care Unit with high morbidity and mortality. Human liver fatty acid-binding protein (L-FABP) as a renal tubular injury biomarker was considered a predictor of AKI; however, high-throughput and sensitive detection methods were still urgently needed. We constructed a sensitive and rapid detection method for detecting L-FABP and for exploring the clinical application of L-FABP as a predictor for AKI. MethodsWe developed an automated detection method of chemiluminescent immunoassay to measure L-FABP and evaluated the analytical performance of the new methodology including analytical selectivity, analytical sensitivity, linear range, the minimum limit of detection (LOD), repeatability, and accuracy. One hundred patients were enrolled in this study to explore the predictive and diagnostic ability for AKI. ResultsThe chemiluminescent immune-based L-FABP assay had outstanding analytical sensitivity including the detection limit of 0.88 ng/ml, and a wide linear range of 2 ng/ml to 160 ng/ml. It also exhibited excellent repeatability with intra-analysis CVs of 8.73%, 4.72%, and 3.79%, respectively, and the inter-analysis CVs of 13.47%, 7.28%, and 5.94%, respectively. The recovery rate assay exhibited a good accuracy with three L-FABP concentration of 99.76%, 102.27%, and 96.92%, respectively. The reference interval of L-FABP was between 0.88 ng/ml and 5.98 ng/ml. The evaluation of predictive and diagnostic performance showed that higher concentration of L-FABP indicated higher risk of AKI occurrence and disease progression. ConclusionsThe clinical application of rapid and sensitive detection method of L-FABP based on the newly developed chemiluminescent immunoassay could offer benefits for patients. L-FABP was a potentially predictive and diagnostic biomarker for AKI.

Aptasensors Are Conjectured as Promising ALT and AST Diagnostic Tools for the Early Diagnosis of Acute Liver Injury

Low-Cost Point-of-Care Monitoring of ALT and AST Is Promising for Faster Decision Making and Diagnosis of Acute Liver Injury

Biomarkers of liver fibrosis detecting with electrochemical immunosensor on clinical serum

A Low-Cost Compact Blood Enzyme Analyzer Based on Optical Sensing for Point-of-care Liver Function Testing.

Application of Molecularly Imprinted Microelectrode as a Promising Point-of-Care Biosensor for Alanine Aminotransferase Enzyme

Portable Dual-Channel Blood Enzyme Analyzer for Point-of-care Liver Function Detection.

Signal-Boosted Electrochemical Lateral Flow Immunoassay for Early Point-of-Care Detection of Liver Cancer Biomarker

Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis

Current trends in electrochemical approaches for liver biomarker detection: a mini-review

Alanine aminotransferase detection using TIT assisted four tapered fiber structure-based LSPR sensor: From healthcare to marine life

Aptameric Fluorescent Biosensors for Liver Cancer Diagnosis

Detection of Biomarkers for Liver Fibrosis Using High‐Throughput Electrochemical Microimmunosensor

A liquid crystal-decorated aptasensing gadget for rapid monitoring of A549 cells: Future portable test kit for lung cancer diagnosis

Lateral Flow Assays Based on Aptamers for Food Safety Applications

Aptamer-based lateral flow assay on-site biosensors

Dual-targets binding protection mediated rolling circle transcription with tandem fluorescent RNA aptamers for label-free detection of liver cancer biomarkers

Shining a light on liver health: advancements in fluorescence-enhanced enzyme biosensors for early disease detection

Point-of-Care Diagnoses and Assays Based on Lateral Flow Test

Facile and cost-effective liver cancer diagnosis by water-gated organic field-effect transistors

An Ultra-miniaturized Inflammation Monitoring Platform Implemented by Long Afterglow Lat-eral Flow Immunoassay

Rapid and sensitive detection of L‐FABP for prediction and diagnosis of acute kidney injury in critically ill patients by chemiluminescent immunoassay